NCT05911178 (GliSyn) is a NA clinical trial of [11C]-UCB-J in Alzheimer Disease, sponsored by Centre Hospitalier St Anne.

Who is sponsoring NCT05911178?

NCT05911178 is sponsored by Centre Hospitalier St Anne.

What drugs are being tested in NCT05911178?

Interventions in NCT05911178: [11C]-UCB-J, [18F]-DPA-714, [18F]-RO-948, [11C]-PiB.

What condition does NCT05911178 study?

NCT05911178 studies Alzheimer Disease.

Is NCT05911178 still recruiting?

NCT05911178 is currently recruiting now. Last updated 13 June 2024.

Last reviewed 2024-06-13 · How we verify

NCT05911178: GliSyn

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

Recruiting now NA Last updated 13 June 2024

What this trial tests

NA trial testing [11C]-UCB-J in Alzheimer Disease in 90 participants. Currently enrolling.

Timeline

18 October 2023

Primary endpoint
17 February 2028

17 April 2028

Quick facts

Lead sponsor	Centre Hospitalier St Anne
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	screening
Enrollment	90
Start date	18 October 2023
Primary completion	17 February 2028
Estimated completion	17 April 2028
Sites	3 locations across France

Drugs / interventions tested

[11C]-UCB-J
[18F]-DPA-714
[18F]-RO-948
[11C]-PiB

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Centre Hospitalier St Anne

Who can join

18 and older, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to analyse, in vivo, the interplay between microglial activation and tau pathology in Alzheimer's disease (AD) using \[18F\]-DPA-714 and \[18F\]-Ro948 tracers by Position Emission Tomography (PET), and their consequences on synaptic density using \[11C\]-UCB-J, a recent PET radioligand. By coupling advanced neuroimaging techniques in AD patients, while comparing them to controls, we will be able to study, for the first time in humans, the interaction between neuroinflammation, tau pathology, synaptic density, and their impact on AD progression. Joint analyses of peripheral immune biomarkers, carried out as a secondary objective, will further aim at defining peripheral correlates of this interplay. Overall, we aim to refine AD subgroup classification in order to improve and to refine the design of new therapeutic trials.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Demystifying the Role of Neuroinflammatory Mediators as Biomarkers for Diagnosis, Prognosis, and Treatment of Alzheimer's Disease: A Review.
Doke RR, Lamkhade GJ, Vinchurkar K, Singh S. · · 2024 · cited 9× · PMID 39416969 · DOI 10.1021/acsptsci.4c00457
Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials.
Harris GA, Hirschfeld LR, Gonzalez MI, Pritchard MC, et al · · 2025 · cited 8× · PMID 40462159 · DOI 10.1186/s13195-025-01775-x

Verify or expand the search:

Other trials of [11C]-UCB-J

Trials testing the same drug.

NCT03577262 — A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density · EARLY_PHASE1 · completed

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Centre Hospitalier St Anne trials

Trials by the same sponsor.

NCT07340736 — Sensory Mechanisms of Manual Dexterity Recovery After Stroke: a Prospective Cohort Study of Prediction and Cerebral Corr · NA · not yet recruiting
NCT07376473 — Psychometric Validation of the MQOL-FR and Descriptive Assessment of Quality of Life in Patients With Meningiomas · not yet recruiting
NCT07395323 — Impact of Relaxation Sessions Using a Virtual Reality Application on the Sleep Quality of Caregivers Working Night Shift · NA · not yet recruiting
NCT07283458 — Assessment of Language Comprehension and Learning in Children Attending Child Psychiatry Services (TICOALA-SOINS) · NA · not yet recruiting
NCT07144956 — Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05911178 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier St Anne
Last refreshed: 13 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05911178.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing